Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The study is designed as a randomized, Double-Blind, Placebo-Controlled, Parallel-Group Proof
of Concept Study (section A) with a conditional dose finding follow up (Section B) to
Evaluate the Efficacy on Cervical ripening, Safety, Tolerability and dose response of
Subcutaneously Administered Tafoxiparin in Term Pregnant, Nulliparous Women with an unripe
cervix undergoing Labor Induction. If the efficacy and safety profiles of Section A are
conclusive in favor of tafoxiparin, the study will continue by adding two additional
tafoxiparin dose groups in Section B.